EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions

Annie Kleynerman iD, Jitka Rybova iD, Mary L Faber, William M McKillop, Thierry Levade, Jeffrey A Medin

Biomolecules · 2023

DOI: 10.3390/biom13020274 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2023. Verfasst von Annie Kleynerman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, Myoclonic Epilepsies, Progressive, Farber Lipogranulomatosis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Midwest Athletes Against Childhood Cancer, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Farber disease (FD) and spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME) are ultra-rare, autosomal-recessive, acid ceramidase (ACDase) deficiency disorders caused by ASAH1 gene mutations. Currently, 73 different mutations in the ASAH1 gene have been described in humans. These mutations lead to reduced ACDase activity and ceramide (Cer) accumulation in many tissues. Presenting as divergent clinical phenotypes, the symptoms of FD vary depending on central nervous system (CNS) involvement and severity. Classic signs of FD include, but are not limited to, a hoarse voice, distended joints, and lipogranulomas found subcutaneously and in other tissues. Patients with SMA-PME lack the most prominent clinical signs seen in FD. Instead, they demonstrate muscle weakness, tremors, and myoclonic epilepsy. Several ACDase-deficient mouse models have been developed to help elucidate the complex consequences of Cer accumulation. In this review, we compare clinical reports on FD patients and experimental descriptions of ACDase-deficient mouse models. We also discuss clinical presentations, potential therapeutic strategies, and future directions for the study of FD and SMA-PME.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Atrophy, SpinalMyoclonic Epilepsies, ProgressiveFarber LipogranulomatosisDistal MyopathiesMutationMyoclonusMiceCeramidesAnimalsHumans

Stichwörter der Autor:innen

Farber diseaseSMA-PMEacid ceramidaseceramidelipogranulomatosislysosomal storage disorder

Substanzen

Ceramides

Autor:innen und Institutionen

  • Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
  • Laboratoire de Biochimie Métabolique, CHU Toulouse, and INSERM U1037, Centre de Recherches en Cancérologie de Toulouse, Université Paul Sabatier, 31062 Toulouse, France.
  • Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

ORCID-Profile: Annie Kleynerman, Jitka Rybova

Förderung

  • Midwest Athletes Against Childhood Cancer, Inc.

Zitieren

APA

Kleynerman, A., Rybova, J., Faber, M. L., McKillop, W. M., Levade, T., & Medin, J. A. (2023). Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions. Biomolecules. https://doi.org/10.3390/biom13020274

Vancouver

Kleynerman A, Rybova J, Faber ML, McKillop WM, Levade T, Medin JA. Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions. Biomolecules. 2023. doi:10.3390/biom13020274

BibTeX
@article{Kleynerman2023,
  author = {Kleynerman, Annie and Rybova, Jitka and Faber, Mary L and McKillop, William M and Levade, Thierry and Medin, Jeffrey A},
  title = {Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13020274}
}
Kostenlos starten →